ValiRx Raises GBP200,000 To Improve "Extremely Weak" Capital Position
ValiRx Raises GBP200,000 To Improve "Extremely Weak" Capital Position
Read moreFri, 01st May 2020 14:33
ValiRx Raises GBP200,000 To Improve "Extremely Weak" Capital Position
Read moreValiRx "Critically Short" Of Working Capital, In Funding Discussions
Read moreValiRx Still Faces Going Out Of Business; Proposes New Share Plan
Read moreValiRx Investors Seek Removal Of Directors Morris And Vainikka
Read moreValiRx's Future In Doubt As Investors Say No To Capital Reogranisation
Read moreUK Shareholder Meetings Calendar - Next 7 Days
Read more(Sharecast News) - Clinical-stage biotechnology company ValiRx updated the market on its subsidiary joint venture, ValiSeek, and its cancer therapeutic, VAL401 on Tuesday.
Read moreValiRx Joint Venture Partner Enters Agreement For VAL401 Funding
Read moreValiRx Raises GBP200,000 To Progress Product Development
Read moreValiRx Reveals "Clear Impact" Of VAL201 On Prostate Cancer Patients
Read more(Sharecast News) - Clinical stage biotechnology company ValiRx announced on Thursday that the US Patent and Trademark Office has granted patent number 10,400,008, titled 'Modulators Of The SRC-Kinase Activity For Preventing Or Treating Metastatic Cancer', to its lead therapeutic compound 'VAL201'.
Read moreValiRx Granted "Key" US Patent Protection For VAL201 Cancer Treatment
Read moreValiRx Raises GBP350,000 Through Placing To Progress Clinical Trials
Read moreValiRx Reports Narrowed Loss In First Half As Expenses Reduce
Read moreValiRx Receives GBP423,000 Research & Development Credit From UK HMRC
Read more